Pharmaceutical Approval Update.

Authors
Category Primary study
JournalP & T : a peer-reviewed journal for formulary management
Year 2017
Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis.
Epistemonikos ID: 93b6f51b6990bb3ea26ee79648ed48a4fe3b21ec
First added on: May 03, 2023